key: cord-0921671-ipj9hofl
authors: Petrone, Linda; Petruccioli, Elisa; Alonzi, Tonino; Vanini, Valentina; Cuzzi, Gilda; Fard, Saeid Najafi; Castilletti, Concetta; Palmieri, Fabrizio; Gualano, Gina; Vittozzi, Pietro; Nicastri, Emanuele; Lepore, Luciana; Grifoni, Alba; Antinori, Andrea; Vergori, Alessandra; Ippolito, Giuseppe; Cantini, Fabrizio; Goletti, Delia
title: In-vitro evaluation of the immunomodulatory effects of baricitinib: implication for COVID-19 therapy
date: 2021-02-25
journal: J Infect
DOI: 10.1016/j.jinf.2021.02.023
sha: 060709c47d83b46747f4b59238d0a546cb1216ab
doc_id: 921671
cord_uid: ipj9hofl

OBJECTIVE: Baricitinib seems a promising therapy for COVID-19. To fully-investigate its effects, we in-vitro evaluated the impact of baricitinib on the SARS-CoV-2-specific-response using the whole-blood platform. METHODS: We evaluated baricitinib effect on the IFN-γ-release and on a panel of soluble factors by multiplex-technology after stimulating whole-blood from 39 COVID-19 patients with SARS-CoV-2 antigens. Staphylococcal Enterotoxin B (SEB) antigen was used as a positive control. RESULTS: In-vitro exogenous addition of baricitinib significantly decreased IFN-γ response to spike- (median: 0.21, IQR: 0.01-1; spike+baricitinib 1000 nM median: 0.05, IQR: 0-0.18; p<0.0001) and to the remainder-antigens (median: 0.08 IQR: 0-0.55; remainder-antigens+baricitinib 1000 nM median: 0.03, IQR: 0-0.14; p=0.0013). Moreover, baricitinib significantly decreased SEB-induced response (median: 12.52, IQR: 9.7-15.2; SEB+baricitinib 1000 nM median: 8, IQR: 1.44-12.16; p<0.0001). Baricitinib did modulate other soluble factors besides IFN-γ, significantly decreasing the spike-specific-response mediated by IL-17, IL-1β, IL-6, TNF-α, IL-4, IL-13, IL-1ra, IL-10, GM-CSF, FGF, IP-10, MCP-1, MIP-1β (p≤0.0156). The baricitinib-decreased SARS-CoV-2-specific-response was observed mainly in mild/moderate COVID-19 and in those with lymphocyte count ≥1 × 10(3)/µl. CONCLUSIONS: Exogenous addition of baricitinib decreases the in-vitro SARS-CoV-2-specific response in COVID-19 patients using a whole-blood platform. These results are the first to show the effects of this therapy on the immune-specific viral response.

CoV-2, reported for the first time in Wuhan (China) and now spread to almost all countries in the world (1) .

Clinical presentations of COVID-19 include mild/moderate disease, severe and critical disease (2) (3) (4) ). An over exuberant production of proinflammatory cytokines and chemokines (5) mainly during critical disease, is a key aspect of SARS-CoV-2 pathogenesis. Therefore, the block of the cascade of proinflammatory immune factors was considered a promising therapeutic approach (6) . Beside the oxygen supply, several therapies were tested as antivirals, chloroquine and hydroxychloroquine, plasma from convalescent COVID-19 patients, corticosteroids or immunomodulators (6) .

Baricitinib, a Janus kinase (JAK) 1/2 inhibitor, is a drug approved for rheumatoid arthritis treatment (7) . This drug was predicted through the BenevolentAI algorithm (8) as candidate for COVID-19 treatment due to its dual effect of reducing cytokine release and potentially viral entry (9, 10) . Indeed, SARS-CoV-2 enters cells binding the Angiotensin-converting enzyme 2 (ACE2) receptor and the endocytosis is regulated by AP2-associated protein kinase-1 (AAK1) and cyclin G-associated kinase (GAK). Therefore, baricitinib-supposed mechanisms are the inhibition of kinases signalling, thus preventing viral-endocytosis, and inhibition of the cytokine release blocking Janus kinases (JAK)1/2. The anti-viral effects of baricitinib were demonstrated in primary human liver spheroids (8) . Baricitinib, administered to COVID-19 patients showed a good safety profile (11) , reduced mortality, intensive care unit (ICU)-admission and viral load detected from nasopharyngeal swabs (12) . Recently, the Adaptive COVID-19 Treatment Trial (ACTT-2) showed that the combination of baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with COVID-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was significantly associated with fewer serious adverse events in the combination group compared to those occurring in the control group (13) . To note that in the SOLIDARITY trial supported by the World Health Organization (14) which was a large study conducted without placebo arm, the therapy with remdesivir was shown to have little or no effect on hospitalized patients with COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.

T-cell immune response specific to SARS-CoV-2 antigens was extensively studied (15) (16) (17) (18) and

we and others also showed that SARS-CoV-2 specific T-cell responses may be measured in patients with COVID-19 using a whole-blood based platform (19, 20) . The whole blood assay is a valid approach to measure antigen-specific responses that has been explored in the field of several infectious diseases (21) (22) (23) (24) (25) . In a disease different from COVID-19 as tuberculosis, T-cellspecific response decreases overtime and this associates with cure (26) (27) (28) (29) (30) .

Therefore, since baricitinib has been suggested as an important therapy for COVID-19, we invitro evaluated the effect of baricitinib on the SARS-CoV-2-specific-response.

The 39 COVID-19-patients were hospitalized inpatients and classified as mild, moderate, severe and critical according to WHO (4) "NO COVID-19"-individuals were enrolled and were healthy donors (HD) (n=8) volunteers from our laboratory or a convenience sample of consecutively patients hospitalized or followed as outpatients for other diseases as bacterial pneumonia (n=2), active tuberculosis (n=5) and latent tuberculosis infection (n=4). Inclusion criteria for "NO COVID-19" was a negative IgG SARS-CoV-2 serology, no symptoms of COVID-19 and in a portion of them, a negative swab for SARS-CoV-2. Demographic and clinical information were collected at enrollment.

Ethical Committee of Lazzaro Spallanzani National Institute of Infectious Diseases (INMI) approved the study (60/2020) that was conducted in April 17 th -July 20 th . Informed, written consent was required to consecutively enroll patients and controls by physicians.

This study was conducted also evaluating samples from COVID-19 patients and "NO COVID-19" individuals who were part of a previous cohort (study approval number 59/2020) (20) . All the enrolled individuals provided an informed written consent. All the participants" data were anonymized and identified by codes.

Baricitinib was kindly provided by Ely Lilly (Indianapolis, IN, USA); the powder was dissolved in dimethylsulfoxide (DMSO), aliquoted and frozen until use. Baricitinib was used at 10 nM and platform from COVID-19 patients (9). SARS-CoV-2 MegaPool of peptides (MP), spike and remainder-antigens MPs, were already described (15, 18, 31) . Briefly, the peptides prediction was carried out starting from the Wuhan-Hu-1 reference isolated (GenBank ID:MN908947); overlapping 15-mers by 10 spanning the entire spike protein (spike; n=253) were derived, while the remainder of the SARS-CoV-2 proteome has been filtered by CD4-specific prediction algorithm using the 7-allele methodology as previously described (remainder-antigens; n=221) (31) . All the peptides were synthesized as crude material (A&A, San Diego, CA), resuspended in DMSO, pooled separately followed by sequential lyophilization steps as previously described.

Whole-blood (600 µl) was stimulated or not with the described MPs at 0.1µg/mL and Staphylococcal Enterotoxin B (SEB) at 200 ng/mL as positive control for 24 hours at 37°C (5% CO2). Baricitinib was added to the culture 1 hour prior antigen stimulation.

Interferon (IFN)-γ levels were evaluated on harvested plasma by an ELISA test routinely used in our lab (www.quantiferon.com). IFN-γ levels" values were subtracted from the unstimulated control. endothelial growth factor (VEGF)] in the leftover plasma from the whole blood assay. The assay was performed as manufacturer instructions using the MagPix system and the Bio-Plex Manager software (all from Bio-Rad). Concentrations below the detection range were considered as 0, whereas concentrations above the detection range were converted to the highest value of the standard curve. Analyte levels were subtracted from the unstimulated control. Moreover, values generated from <50 bead counts reading were excluded from the final analysis.

SARS-CoV-2 IgG ELISA was performed according to the manufacturer"s instructions (DIESSE Diagnostica Senese S.p.a., Monteriggioni, Italy). The ratio between the optical density (OD) value of the sample and that of the cut-off reagent (index) has been calculated. The sample is considered positive if the index is >1.1, doubtful if the index is between 1.1 and 0.9, negative if the index is <0.9. In "NO COVID-19"-group, samples with a positive ELISA score, were tested with an indirect immunofluorescence (IF) as previously described (20) .Although IF has been described as a test with high sensibility/specificity (32), here was used as confirmatory test as it is an home-made test.

Data were analyzed using SPSS software (Version 19 for Windows, Italy SRL, Bologna, Italy), and GraphPad (GraphPad Prism 8 XML ProjecT). Kolmogorov-Smirnov test was performed and statistics was performed accordingly. For continuous measures, medians and IQR were calculated; the Friedman or Kruskal-Wallis tests were used for comparisons among several groups and the Wilcoxon or Mann-Whitney U tests with Bonferroni correction for pairwise comparisons. Chi square test was used for categorical variables. Spearman Rank Correlation was used for correlations with the following definitions: rs>0.7 was considered high correlation, 0.7<rs>0.5 moderate correlation and rs<0.5 low correlation.

We enrolled 58 subjects: 39 COVID-19 patients and 19 "NO COVID-19" individuals.

COVID-19 patients were classified based on disease severity (4) in mild (n=12, 30.8%), moderate (n=16, 41.0%), severe (n=3, 7.7%) and critical (n=8, 20.5%).

Within the "NO COVID-19"-group, 7/19 had a negative swab result (swab performed within a week from the draw blood). Within the remaining 12 subjects that did not undergo swab testing, 8/12 were lab workers and have been evaluated as healthy up to the following 6 months after enrollment; the remaining 4/12 were subjects with LTBI (n=3) or with active TB (n=1) and they were all followed by our clinic for the appropriate therapy. None of these 4 individuals developed COVID-19 symptoms after more than 6 months from the study enrolment. One HD had a positive IgG-serology by ELISA; however, the IF showed an antibody pattern not specific for SARS-CoV-2. Therefore, all "NO COVID-19"-individuals were considered negative for SARS-CoV-2-serology.

The demographic and clinical characteristics of the enrolled individuals are shown in Table 1 . A flow chart of the subjects analysed is included as Supplementary Figure 1 .

We In "NO COVID-19" we observed that baricitinib decreased the IFN-γ response only if this response was present.

We evaluated the impact of baricitinib on the IFN-γ response to SARS-CoV-2 peptides in COVID-19 patients stratifying for disease severity and lymphocyte counts. Only IFN-γ values>0 IU/mL were included in the analysis. As expected, patients with mild disease were more likely to have lymphocyte count >1 x10 3 /µl (33) .

Exogenous addition of baricitinib at 10 nM and at 1000 nM significantly decreased the spike IFN-γ response in patients with ≥1<2 x10 3 /µl lymphocytes (p=0.0024 and p=0.0012, respectively) and in patients with more than 2 x10 3 /µl lymphocytes (p=0.0039) (Figure 2A) . Baricitinib Figure 5B, D) .

Baricitinib shuts down the signal of several cytokines by suppressing JAK1/JAK2. Therefore, we evaluated the effect of baricitinib on the immune response elicited by SARS-CoV-2 peptides analyzing the production of several cytokines, chemokines and growth factors by multiplex technology (Figure 3 and Supplementary Figures 6-8) . Multiplex analysis was carried out in 13 COVID-19 patients from whom enough plasma-stimulated sample was available. Baricitinib at 1000 nM significantly decreased the in vitro cytokine spike-specific response mediated by the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α (p=0.0039, Figure 3A -C respectively), the Th1 and Th17 cytokines IFN-γ and IL-17 (p=0.0068 and p=0.0039, Figure 3D -E respectively), the Th2-cytokines IL-4 and IL-13 (p≤0.0098 and p≤0.0098, Figure 3F -G respectively), the immunomodulatory factors IL-10 and IL-1ra (p= 0.0078 and p=0.002, Figure 3H -I, respectively), the chemokines IP-10, MCP-1 and MIP-1β (p≤0.0068, p=0.0024 and p≤0.0029, Figure 3J -L respectively) and the growth factors FGF and GM-CSF (p≤0.0137 and p=0.0156, Figure 3M -N respectively). Baricitinib at 1000 nM decreased also IL-1β and IP-10 production in response to remainder-antigens (p=0.0078 and p=0.0098, Figure 3O -P respectively). Moreover, although not significant, a trend of decreased levels of IL-2, IL-5, IL-12 in response to spike and of IFN-γ, MCP-1 and TNF-α in response to remainder-antigens was also observed (p≤0.04) (Supplementary Figure 6) . Neither significant differences in response to spike for the other factors tested (Supplementary Figure 7) , nor significant modulations in response to remainder-antigens (Supplementary Figure 8) were observed.

COVID-19 is a pandemic viral disease caused by the novel coronavirus SARS-CoV-2.

Identification of effective therapy is crucial before large-scale vaccine administration would be available (6) . Baricitinib combined with ramdesavir has been recently shown in the ACTT-2 randomized controlled trial to be superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with COVID-19, notably among those receiving high-flow oxygen or noninvasive ventilation (13) . This is likely due to the immunemodulatory and potential antiviral effects of the drug (8) (9) (10) 12) . However it is unknown the effect of this treatment on the modulation of the SARS-CoV-2-specific-response.

We showed for the first time in a whole-blood experimental setting, that exogenous in vitro addition of baricitinib decreased SARS-CoV-2-specific response to a broad set of immune factors including Th1, Th2 and chemokines. The effect of baricitinib in decreasing the viral-induced immune response was specific for COVID-19 mainly in patients with mild/moderate disease and with a lymphocytes count higher than 1x10 3 /µl. These results highlight how this drug may be beneficial for COVID-19 treatment.

We recently showed that the immune response to spike peptides in COVID-19 patients is characterized by a high IFN-γ response (20) and by the predominance of Th1 and low magnitude of Th2 cytokines (20) . Here we confirm these findings and demonstrated that, in COVID-19 patients, baricitinib decreased the levels of a broad range of immune factors as IFN-γ, proinflammatory cytokines (IL-1β, IL-6 and TNF-α), IL-17, Th2 cytokines (IL-4, IL-13), IL-1ra, IL-10, growth factors (GM-CSF, FGF), chemokines (IP-10, MCP-1, MIP-1β). These factors are produced by both T and B cells as well as innate immunity cells and were already described as considerably increased in COVID-19 patients (2, 34) and associated with COVID-19 severity (5), although recent studies suggest that adaptive immune response is crucial to limit the severity of the disease (35) .

Our results indicate that exogenous addition of baricitinib in vitro shuts down the SARS-CoV-2specific immune response, as shown in COVID-19-treated patients (36) . Moreover, we observed an impact of baricitinib on FGF. Interestingly, FGF gene is up-regulated during the Middle East respiratory syndrome coronavirus (MERS-CoV) infection (37) . MERS-CoV is a virus close to SARS-CoV-2; therefore, this factor may have a role also in SARS-CoV-2 pathogenesis and its modulation may be involved in COVID-19 outcome.

Baricitinib does decrease the in vitro viral-specific response in patients with a high lymphocytes count and with mild/moderate COVID-19 and also in the severe and critical cases tested, although in these last the difference did not reach statistical significance. These data are in line with clinical studies in which baricitinib showed a good clinical efficacy in patients with mildmoderate disease (11, 12) . Moreover, baricitinib in vitro decreases the IFN-γ levels in response to SEB superantigen. Altogether, these in vitro results underline that baricitinib acts when a massive cytokine release takes place suggesting that clinically, this drug may be useful prior the manifestation of an exacerbated immune response. Consistently, baricitinib-treated COVID-19 patients have decreased pro-inflammatory cytokines (IL-6, TNF-α and IL-1β) compared to baseline levels (12, 36, 37) . Moreover, the overtime evaluation of the whole-blood SARS-CoV-2specific response may be useful for monitoring both, the biological effects of the drug clinically administered to patients and for disease outcome, as reported in other viral diseases as Cytomegalovirus (CMV). Indeed, this whole-blood assay has been already exploited to monitor congenital CMV (38) .

Cytokine responses after MPs stimulations were randomly found in "NO COVID-19" patients as previous reported (15, 16, 18, 20, 39) and baricitinib decreased the spike-specific response found mainly only in the 3 subjects in whom IFN-γ response was above the cut-off values (20) .

In addition to the important results of the ACTT-2 study (13) , clinical administration of baricitinib was shown in smaller studies to improve the clinical conditions in moderate pneumonia of COVID-19 patients after 14 days of oral therapy and reducing ICU transfer and death. The clinical findings associated to a reduction of cytokines levels in plasmas as IL-6 (12) and other immune factors as C-reactive proteins (12, 40) and of viral load as measured by decreased number of positive score to nasopharyngeal swabs. All these data indicated that this drugs had both antiinflammatory and antiviral effects. In patients with rheumatoid arthritis, baricitinib therapy has been associated with a higher risk of venous thromboembolism. However in the ACTT-2, this adverse event was similar in the combination group and the control group and the difference was not significant. The absence of thromboembolism risk has been likely due to the prophylaxis with low-weight molecular heparin and to the fact that the baricitinib treatment was provided only for 2 weeks.

It is important to note that in other infectious diseases, i.e. tuberculosis, a decreased T-cell specific response, in this case to M. tuberculosis antigens, has been associated to cure (26) (27) (28) (29) (30) .

However, for the cure of the viral infection, evidence indicates that the cellular response, mainly Th1-mediated, remains essential (41) .

The limitations of this study include the small size of the samples evaluated and the lack of a prior sample size calculation. However, this is the first study analysing the effect of the baricitinib on the modulation of a specific response to SARS-CoV-2 in an easy-to-use system as whole-blood platform and deeply analysing this effect on a broad range of immune factors. The results obtained are robust because confirmed across the different COVID-19 stages and using several immune parameters beside IFN-γ. Another limit is the lack of the evaluation of the effect of clinically administered baricitinib on SARS-CoV-2-specific response in COVID-19 patients although it has been shown that baricitinib clinically administered decreases the pro-inflammatory plasma cytokines and increases the circulating number of B-and T-cells, in particular CD4 T-cells and within them, the effector memory cell subset (40) . No overtime evaluation of the viral-specific-T cell response has been done yet.

In conclusion, we demonstrated for the first time to our knowledge that baricitinib down modulates the SARS-CoV-2-specific response in a whole-blood experimental assay. These results provide insights on the mechanisms potentially involved for the beneficial effects of baricitinib for COVID-19 treatment.

Study conception and design: DG. 

Report on COVID-19 pandemic

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management

Clinical management of COVID-19. Interim guidance

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review

Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients

COVID-19: combining antiviral and anti-inflammatory treatments

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19

Repurposed Antiviral Drugs for COVID-19 -Interim WHO Solidarity Trial Results

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response

A whole blood test to measure SARS-CoV-2 specific response in COVID-19 patients

Global Tuberculosis Network (GTN) and members(#) of ESCMID Study Group for Mycobacterial Infections (ESGMYC)

T-cell diagnostic test for cystic echinococcosis based on Antigen B peptides

IL-4 specificresponse in whole blood associates with human Cystic Echinococcosis and cyst activity

Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients

Interferon-γ Release Assay for Cytomegalovirus (IGRA-CMV) for Risk Stratification of Posttransplant CMV Infection: Is It Time to Apply IGRA-CMV in Routine Clinical Practice?

Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load

Impact of antiretroviral and tuberculosis therapies on CD4+ and CD8+ HIV/M. tuberculosis-specific T-cell in co-infected subjects

IFNγ/TNFα specific-cells and effector memory phenotype associate with active tuberculosis

Use of a T cellbased assay for monitoring efficacy of antituberculosis therapy

Region of difference 1 antigenspecific CD4+ memory T cells correlate with a favorable outcome of tuberculosis

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

SARS-CoV-2 has been circulating in northeastern Brazil since February 2020: evidence for antibody detection in asymptomatic patients

Correction: Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19

MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2

Immune Monitoring Using QuantiFERON®-CMV Assay in Congenital Cytomegalovirus Infection: Correlation With Clinical Presentation and CMV DNA load

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Baricitinib restrains the immune dysregulation in severe COVID-19 patients

Warriors of SARS-CoV

Acknowledgements: This work was supported by Eli Lilly and Company (contract number ID:2889530D-8A27-4FD8-A3CA-9384E65939F7), by Line one-Ricerca Corrente "Infezioni Emergenti The authors are grateful to all the patients and nurses who helped to conduct this study. In particular we thank Sara Pantanella, Daniela Milordo, Luciana Dell"Arciprete and Lorella Tinari.We wish to acknowledge Alessandro Sette for helpful discussions and providing peptide reagents.The authors gratefully acknowledge the Collaborators Members of the National Institute for Infectious Diseases (INMI) COVID-19 study group: Maria Alessandra Abbonizio, Amina